About Cue Biopharma, Inc.
https://www.cuebiopharma.comCue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders.
CEO
Usman Azam
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 15
Ratings Snapshot
Rating : C-
Most Recent Analyst Grades
Grade Summary
Showing Top 1 of 1
Price Target
Institutional Ownership
BLEICHROEDER LP
Shares:6.82M
Value:$2.33M
CATALYTIC WEALTH RIA, LLC
Shares:3.43M
Value:$1.17M
VANGUARD GROUP INC
Shares:3.04M
Value:$1.04M
Summary
Showing Top 3 of 64
About Cue Biopharma, Inc.
https://www.cuebiopharma.comCue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $2.15M ▼ | $9.61M ▼ | $-7.45M ▲ | -346.58% ▼ | $-0.07 ▲ | $-7.29M ▲ |
| Q2-2025 | $2.95M ▲ | $11.59M ▼ | $-8.48M ▲ | -287.14% ▲ | $-0.09 ▲ | $-7.64M ▲ |
| Q1-2025 | $421K ▼ | $12.72M ▲ | $-12.26M ▼ | -2.91K% ▼ | $-0.17 ▼ | $-11.25M ▼ |
| Q4-2024 | $1.58M ▼ | $11.21M ▼ | $-9.5M ▼ | -602.54% ▼ | $-0.13 ▲ | $-9.24M ▼ |
| Q3-2024 | $3.34M | $12.15M | $-8.66M | -259.59% | $-0.17 | $-7.59M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $18.67M ▼ | $31.64M ▼ | $18.4M ▼ | $13.25M ▼ |
| Q2-2025 | $27.96M ▲ | $40.71M ▲ | $22.55M ▲ | $18.16M ▲ |
| Q1-2025 | $13.14M ▼ | $22.25M ▼ | $15.67M ▲ | $6.58M ▼ |
| Q4-2024 | $23.39M ▼ | $32.19M ▼ | $14.69M ▼ | $17.5M ▼ |
| Q3-2024 | $32.42M | $44.81M | $19.44M | $25.37M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-7.45M ▲ | $-9.02M ▼ | $-6.77M ▼ | $1K ▼ | $-15.79M ▼ | $-9.02M ▼ |
| Q2-2025 | $-8.48M ▲ | $-3.42M ▲ | $-27K ▲ | $17.8M ▲ | $14.36M ▲ | $-3.44M ▲ |
| Q1-2025 | $-12.26M ▼ | $-8.17M ▲ | $-150K ▼ | $-1M ▼ | $-9.32M ▲ | $-8.32M ▲ |
| Q4-2024 | $-9.5M ▼ | $-9.03M ▼ | $-1K ▼ | $-932K ▼ | $-9.96M ▼ | $-9.03M ▼ |
| Q3-2024 | $-8.66M | $-7.53M | $98K | $9.82M | $2.39M | $-7.53M |
CEO
Usman Azam
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 15
Ratings Snapshot
Rating : C-
Most Recent Analyst Grades
Grade Summary
Showing Top 1 of 1
Price Target
Institutional Ownership
BLEICHROEDER LP
Shares:6.82M
Value:$2.33M
CATALYTIC WEALTH RIA, LLC
Shares:3.43M
Value:$1.17M
VANGUARD GROUP INC
Shares:3.04M
Value:$1.04M
Summary
Showing Top 3 of 64